Conrad (for Evan Seigerman)'s questions to Replimune Group Inc (REPL) leadership • Q4 2025
Question
Conrad, on behalf of Evan Seigerman at BMO Capital Markets, inquired about Replimune's manufacturing resiliency plans and the drivers of its attractive cost of goods profile for RP1.
Answer
CEO Sushil Patel explained that RP1 is manufactured in-house at Replimune's dedicated U.S. facility, a strategic decision that provides an attractive cost of goods. He assured that the facility has sufficient inventory and built-in redundancy to support a broad launch and long-term demand, with plans to also produce pipeline candidates RP2 and RP3 there in the future.